Sunesis Pharmaceuticals, Inc. (NASDAQ:SNSS)

CAPS Rating: 3 out of 5

The Company is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel small molecule therapeutics for oncology and other unmet medical needs.

Results 1 - 20 of 20

Recs

0
Member Avatar pchop12316 (84.18) Submitted: 9/2/2015 10:15:35 AM : Outperform Start Price: $1.15 SNSS Score: +0.62

likely to excel

Recs

1
Member Avatar zzlangerhans (99.79) Submitted: 9/1/2015 11:38:05 PM : Outperform Start Price: $1.03 SNSS Score: +12.36

One of the most frustrating things about the biopharma sector is that logic is often completely insufficient as a basis for a profitable trade. Despite applying logic to my analysis of Sunesis and being completely correct about the outcome of every true catalyst, I've been forced to endure long periods of negative score on my picks and of course missed opportunities to profit on this extremely volatile stock.

I originally pegged Sunesis's VALOR trial as a probable failure due to the expansion of enrollment at interim analysis and was eventually proved correct, although the stock rose to unfathomable heights ahead of the splatterfest when negative trial results were released. When the stock started to migrate upward again on optimistic pronouncements from management that they would attempt to submit NDA and MAA based on the failed data I dropped another scornful red thumb on the stock. This also went 100 points red until the FDA slapped the company down last week with instructions to perform new clinical trials of vosaroxin in AML prior to an NDA submission. The EMA, on the other hand, did not discourage an MAA but in general the EU tends to be much more lenient in that regard.

Sunesis stock is down dramatically but I wouldn't bet the hemorrhage is over yet. Once the MAA is inevitably submitted it could easily be a year and a half before CHMP renders an opinion, and it's unlikely Sunesis will make it that far without new financing. Nevertheless, I like to mark my interesting stocks with a thumb even if it turns out to be early, just to help me remember to keep a close eye on them.

Recs

0
Member Avatar chenjesu (75.49) Submitted: 8/27/2015 2:07:19 PM : Outperform Start Price: $1.04 SNSS Score: +13.98

portefeuille

Recs

0
Member Avatar NHWeston102 (21.56) Submitted: 8/27/2015 9:34:31 AM : Outperform Start Price: $1.06 SNSS Score: +11.51

One of the most volatile Biotechs in the business but they have backing, they have cancer treatments under FDA testing, and a terrific risk-reward ratio. They bounce a lot so fasten your seatbelt with SNSS!!

Recs

0
Member Avatar clangmead (33.19) Submitted: 8/27/2015 7:55:31 AM : Outperform Start Price: $1.08 SNSS Score: +9.18

mp1

Recs

0
Member Avatar helicopterfool (98.55) Submitted: 8/26/2015 11:39:51 AM : Outperform Start Price: $1.02 SNSS Score: +11.05

zz & porte rec

Recs

0
Member Avatar OilRulesTheWorld (34.50) Submitted: 7/24/2015 12:54:04 PM : Outperform Start Price: $1.00 SNSS Score: +24.11

Should see a Big Dead Count Bounce from this level.

Recs

0
Member Avatar HealthcareGuy (99.73) Submitted: 7/22/2015 12:58:32 PM : Outperform Start Price: $3.54 SNSS Score: -59.42

They will refile- sell that news

Recs

0
Member Avatar mdriver78 (62.27) Submitted: 4/9/2015 8:13:05 AM : Outperform Start Price: $1.03 SNSS Score: +19.95

FDA Trader Selection

Recs

0
Member Avatar SkepBioInvestor (95.25) Submitted: 1/19/2015 5:22:19 PM : Outperform Start Price: $2.50 SNSS Score: -49.72

Drug is active and potential registration will drive the stock up

Recs

0
Member Avatar pchop123 (81.22) Submitted: 7/31/2014 12:41:04 PM : Underperform Start Price: $6.63 SNSS Score: +83.04

overpriced

Recs

0
Member Avatar motleyflyer (< 20) Submitted: 1/30/2013 7:21:31 AM : Outperform Start Price: $4.97 SNSS Score: -96.52

Pharma Research

Recs

0
Member Avatar SnarkyApple (61.36) Submitted: 9/27/2012 4:32:36 PM : Underperform Start Price: $5.67 SNSS Score: +114.95

Shenanigans.

Recs

0
Member Avatar theMANzalone (55.76) Submitted: 3/14/2012 4:05:12 PM : Outperform Start Price: $2.45 SNSS Score: -91.67

2013 will kick into gear

Recs

0
Member Avatar DanishDynamite (< 20) Submitted: 7/22/2011 4:38:21 AM : Outperform Start Price: $2.04 SNSS Score: -87.87

Finally, found its price range, before we reach a yes or no, it will spike on phase III news.

Recs

0
Member Avatar archingstocks (< 20) Submitted: 1/10/2011 5:23:50 PM : Outperform Start Price: $2.97 SNSS Score: -113.91

Well funded, well staffed, good drug

Recs

2
Member Avatar akshara3000 (< 20) Submitted: 1/5/2011 6:10:19 PM : Outperform Start Price: $3.00 SNSS Score: -113.38

If phase 3 trial info is released midterm through the study, and it is as positive and consistent as previous results, the stock will jump remarkably, especially after being beaten down so badly since mid 2010. This thing could easily double or triple in a years time, since there is no reason not to believe that phase 3 results will be outstanding. That does not guarantee approval, but there should be money to be made well before that stage of the process. 25k shares at 66 cents and I will hold long term

Recs

0
Member Avatar 1997amer (< 20) Submitted: 1/1/2011 5:05:18 PM : Outperform Start Price: $3.12 SNSS Score: -116.68

It is an oncology orphan drug!!! very likely wii be approved even with 4 -5 weeks improved survival.

Recs

0
Member Avatar motleyjmw (< 20) Submitted: 1/19/2007 1:48:31 PM : Outperform Start Price: $30.00 SNSS Score: -141.29

Biogen Idec is a beneficial owner

Recs

0
Member Avatar theminc (< 20) Submitted: 10/6/2006 9:28:50 PM : Underperform Start Price: $30.00 SNSS Score: +149.86

Early in the IPO. Solid company with a lot of bright minds. Results of clinical trial results will determine level of success.

Results 1 - 20 of 20

Featured Broker Partners


Advertisement